Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is in early talks to raise new funding at a valuation of at least $40 billion — and possibly as high as $50 billion — according to a Bloomberg report published October 8 and confirmed by subsequent trade coverage. The figure would more than double the roughly $17.5 billion valuation the London- and New York-based company carried just months earlier, after it closed a $2.1 billion Series B in May led by Thrive Capital with participation from Alphabet and the UK’s sovereign AI fund. Remarkably, the talks are unfolding before Isomorphic has dosed a single patient in a clinical trial; the company says it plans to begin first-in-human testing by the end of 2026.
From AlphaFold to Drug Design
Isomorphic Labs was founded in 2021 by DeepMind chief executive Demis Hassabis as a way to commercialize the scientific breakthrough behind AlphaFold, the protein-structure-prediction system that earned Hassabis and colleague John Jumper a share of the 2024 Nobel Prize in Chemistry. Where AlphaFold predicts how proteins fold, Isomorphic’s core product, the Isomorphic Drug Design Engine, extends that modeling to predict how small-molecule drugs will bind to disease-related proteins — in theory compressing years of wet-lab trial and error into a computational design process. The company has raised roughly $2.7 billion in disclosed external funding since its founding, including a $600 million Series A in March 2025, while Alphabet remains its majority shareholder.
Big-Pharma Partners, Real Money on the Table
Isomorphic’s commercial credibility so far rests on partnerships rather than its own approved products. Deals announced in 2024 with Eli Lilly and Novartis carry potential milestone payments exceeding $3 billion combined, contingent on the company’s AI-designed candidates hitting development targets, and the company has since added Johnson & Johnson as a partner while opening additional research sites in the U.S. and Switzerland. Those agreements give Isomorphic a revenue path that doesn’t depend on its own candidates reaching approval, but the headline figures are milestone-based and largely theoretical until specific compounds clear specific hurdles.
The Bull Case: A Platform, Not a Pipeline Bet
Investors willing to back a $40 billion-plus valuation are effectively betting on Isomorphic as infrastructure for the entire pharmaceutical industry rather than on any single drug candidate succeeding or failing. If its AI models meaningfully shorten the design phase of drug discovery — the part of the pipeline before a single patient is ever dosed — the argument goes, that efficiency compounds across every partner program the company runs simultaneously, unlike a traditional biotech whose value rises or falls with one or two lead assets.
The Skeptics’ Case: No Patients, No Proof
The company’s own disclosed timeline is also the clearest basis for caution: as of the funding talks, Isomorphic has not released clinical data and has not dosed a single human patient, meaning the entire valuation rests on computational predictions and partner confidence rather than any clinical validation. The broader AI-drug-discovery sector has already supplied a cautionary data point — a widely cited Nature Medicine analysis found that AI-discovered drugs have so far failed in Phase 2 trials at rates similar to conventionally discovered drugs, undercutting the industry narrative that AI-designed molecules are inherently more likely to work once they reach humans. A valuation north of $40 billion for a company that has not yet dosed a patient would place Isomorphic’s paper worth well above that of many biotechs with approved, revenue-generating drugs, a gap that will only be resolved once first-in-human data actually arrives.
What’s Next
The talks remain preliminary, and no deal has been finalized, but the scale of the number under discussion underscores how much capital is chasing the premise that AI can compress the drug discovery timeline — even as the industry’s own trial data urges patience. The real inflection point will come at the end of 2026, when Isomorphic has said it expects to begin first-in-human trials; results from that first cohort, whenever they arrive, will offer the first direct test of whether the AlphaFold-derived modeling that justified a Nobel Prize in protein science translates into molecules that actually work in people.
Photo: Pexels / PIXABAY via Pixabay
